Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc.

Oct 23 • 10:20AM ET

55.44

Dollar change +0.65
Percentage change 1.18	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI VB VXF VBK XBI IBB IWP FXH SCHA IWF

Index	-	P/E	-	EPS (ttm)	-7.29	Insider Own	6.46%	Shs Outstand	92.17M	Perf Week	-3.93%
Market Cap	5.11B	Forward P/E	-	EPS next Y	-5.28	Insider Trans	-1.00%	Shs Float	86.21M	Perf Month	-3.56%
Income	-585.12M	PEG	-	EPS next Q	-1.48	Inst Own	96.70%	Short Float	3.35%	Perf Quarter	23.03%
Sales	481.30M	P/S	10.62	EPS this Y	22.42%	Inst Trans	10.70%	Short Ratio	4.26	Perf Half Y	25.19%
Book/sh	4.70	P/B	11.80	EPS next Y	17.55%	ROA	-39.94%	Short Interest	2.89M	Perf Year	73.23%
Cash/sh	8.35	P/C	6.64	EPS next 5Y	37.90%	ROE	-208.43%	52W Range	31.52 - 60.37	Perf YTD	15.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.75%	ROI	-45.00%	52W High	-8.17%	Beta	0.57
Dividend TTM	-	Quick Ratio	3.39	Sales past 5Y	63.06%	Gross Margin	83.47%	52W Low	75.87%	ATR (14)	1.69
Dividend Ex-Date	-	Current Ratio	3.54	EPS Y/Y TTM	28.85%	Oper. Margin	-114.03%	RSI (14)	50.07	Volatility	2.71% 3.05%
Employees	1276	Debt/Eq	2.14	Sales Y/Y TTM	19.47%	Profit Margin	-121.57%	Recom	1.20	Target Price	92.10
Option/Short	Yes / Yes	LT Debt/Eq	2.01	EPS Q/Q	32.57%	Payout	-	Rel Volume	0.55	Prev Close	54.79
Sales Surprise	19.34%	EPS Surprise	8.47%	Sales Q/Q	35.75%	Earnings	Aug 01 AMC	Avg Volume	677.50K	Price	55.44
SMA20	0.65%	SMA50	-0.80%	SMA200	16.42%	Trades		Volume	63,788	Change	1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151

Show Previous Ratings

Oct-18-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-24 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta (GlobeNewswire)
Oct-03-24 04:30PM	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Sep-26-24 08:00AM	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting (GlobeNewswire)
Sep-18-24 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:07AM	Loading…
Sep-05-24 01:07AM	Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:30PM	Ultragenyx to Participate in Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.62%
Aug-06-24 10:45AM	3 Genomics Stocks That May Transform Personalized Medicine (InvestorPlace)
Aug-02-24 08:15AM	Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD Global Investments LP (Business Wire) +14.31%
07:44AM	Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up (Zacks)
Aug-01-24 04:17PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Jul-25-24 04:05PM	Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
08:00AM	Loading…
Jul-24-24 08:00AM	Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium (GlobeNewswire)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
Jul-19-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-18-24 09:03AM	Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans (Zacks)
Jul-17-24 04:05PM	Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program (GlobeNewswire)
Jun-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-13-24 08:49PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.44%
10:15AM	Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug (Zacks)
05:12AM	Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last? (Zacks)
03:14AM	Insider Sale: EVP and Chief Legal Officer Karah Parschauer Sells Shares of Ultragenyx ... (GuruFocus.com)
Jun-12-24 04:05PM	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.83%
04:00PM	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
10:46AM	Ultragenyx (RARE) Posts New Data From Bone Disease Study (Zacks)
07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive)
05:47PM	Loading…
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-04-24 04:05PM	Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 10:36AM	Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study (Zacks)
May-30-24 04:00PM	Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
May-22-24 02:27PM	Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells (Benzinga)
May-17-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-24 04:30PM	Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference (GlobeNewswire)
May-04-24 10:24AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:01PM	Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ... (GuruFocus.com)
12:22PM	Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
May-02-24 08:58PM	RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ... (GuruFocus.com)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
Jan-25-24 04:05PM	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jan-19-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 02:41PM	Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 (Investor's Business Daily)
Jan-09-24 06:20PM	After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright (Zacks)
Jan-08-24 12:18PM	Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint (Zacks)
07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Jan-07-24 11:00AM	Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones (GlobeNewswire)
Jan-04-24 08:12AM	Ultragenyx (RARE) Posts Update From AS Study of GTX-102 (Zacks)
08:00AM	Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Jan-03-24 08:00AM	Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome (GlobeNewswire)
Jan-02-24 04:05PM	Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-21-23 05:21PM	Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims (The Wall Street Journal)
04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-23 09:29AM	Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome (PR Newswire)
08:00AM	Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-15-23 10:18AM	5 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Nov-20-23 04:30PM	Ultragenyx to Participate at Investor Conferences in November (GlobeNewswire)
Nov-17-23 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 05:00PM	Ultragenyx to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-23 01:12PM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks) +6.09%
Nov-02-23 06:26PM	Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2023 Earnings: Revenue Grows by 8% Year-Over-Year (GuruFocus.com)
04:36PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-23 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire) +5.12%
Oct-25-23 06:17AM	Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc (GuruFocus.com)
Oct-23-23 04:01PM	Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Oct 10 '24	Sale	52.76	7,465	393,853	92,301	Oct 11 04:48 PM
KAKKIS EMIL D	President & CEO	Sep 03 '24	Sale	55.85	20,000	1,117,000	2,223,985	Sep 05 11:53 AM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '24	Sale	56.19	91	5,113	41,551	Sep 05 11:50 AM
KAKKIS EMIL D	Officer	Sep 03 '24	Proposed Sale	55.85	20,000	1,117,096		Sep 03 04:40 PM
KAKKIS EMIL D	President & CEO	Aug 06 '24	Sale	50.17	20,000	1,003,400	2,243,985	Aug 07 02:48 PM
KAKKIS EMIL D	Officer	Aug 06 '24	Proposed Sale	50.17	20,000	1,003,418		Aug 06 04:28 PM
Sanders Corazon (Corsee) D.	Director	Jul 02 '24	Sale	40.98	584	23,932	12,009	Jul 03 02:07 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 12 '24	Sale	45.00	9,806	441,270	57,981	Jun 12 07:47 PM
Sanders Corazon (Corsee) D.	Director	Jun 10 '24	Sale	41.10	1,737	71,391	7,248	Jun 10 07:58 PM
Crombez Eric	EVP and Chief Medical Officer	May 02 '24	Sale	43.66	354	15,456	48,431	May 03 03:23 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM
Kassberg Thomas Richard	CBO & EVP	Mar 11 '24	Sale	49.93	11,509	574,644	252,823	Mar 12 01:41 PM
Fust Matthew K	Director	Mar 07 '24	Sale	50.88	12,195	620,443	14,860	Mar 11 12:54 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 01 '24	Sale	53.76	3,756	201,923	67,340	Mar 05 08:22 PM
Kassberg Thomas Richard	CBO & EVP	Mar 01 '24	Sale	53.76	1,011	54,351	264,332	Mar 05 08:19 PM
Pinion John Richard	See Remarks	Mar 01 '24	Sale	53.76	4,173	224,340	89,268	Mar 05 08:15 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 01 '24	Sale	53.76	341	18,332	41,380	Mar 05 08:13 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 01 '24	Sale	53.76	1,238	66,555	48,927	Mar 05 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 01 '24	Sale	53.76	4,768	256,328	67,163	Mar 05 08:08 PM
KAKKIS EMIL D	President & CEO	Feb 07 '24	Sale	45.00	30,000	1,350,000	539,770	Feb 08 03:49 PM
KAKKIS EMIL D	President & CEO	Dec 29 '23	Sale	47.87	30,000	1,436,100	569,770	Jan 02 04:07 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Jan 02 '24	Option Exercise	21.00	3,000	63,000	27,892	Jan 02 04:06 PM

Open in Screener

VIR

Vir Biotechnology Inc

Oct 23 • 10:20AM ET

7.56

Dollar change -0.05
Percentage change -0.66	%

Healthcare • Biotechnology • USA • NASD

VIR Vir Biotechnology Inc daily Stock Chart

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN SNY NVAX

| Held by: IJR VTI VB IWM XBI VBK VXF IJS IWN SPSM

Index	RUT	P/E	-	EPS (ttm)	-3.58	Insider Own	35.50%	Shs Outstand	134.78M	Perf Week	-3.95%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-3.77	Insider Trans	-0.03%	Shs Float	88.14M	Perf Month	0.26%
Income	-483.04M	PEG	-	EPS next Q	-1.05	Inst Own	51.36%	Short Float	6.50%	Perf Quarter	-29.09%
Sales	78.88M	P/S	13.09	EPS this Y	26.24%	Inst Trans	-1.28%	Short Ratio	7.68	Perf Half Y	-5.98%
Book/sh	10.50	P/B	0.72	EPS next Y	-11.34%	ROA	-24.69%	Short Interest	5.73M	Perf Year	-7.47%
Cash/sh	8.53	P/C	0.89	EPS next 5Y	7.00%	ROE	-29.78%	52W Range	7.12 - 13.09	Perf YTD	-24.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.12%	ROI	-31.60%	52W High	-42.25%	Beta	0.45
Dividend TTM	-	Quick Ratio	12.51	Sales past 5Y	421.39%	Gross Margin	73.88%	52W Low	6.17%	ATR (14)	0.28
Dividend Ex-Date	Nov 03, 2010	Current Ratio	12.51	EPS Y/Y TTM	-83.41%	Oper. Margin	-648.66%	RSI (14)	46.03	Volatility	2.94% 3.89%
Employees	587	Debt/Eq	0.08	Sales Y/Y TTM	-83.93%	Profit Margin	-612.40%	Recom	1.78	Target Price	31.25
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	30.09%	Payout	-	Rel Volume	0.37	Prev Close	7.61
Sales Surprise	-59.14%	EPS Surprise	-13.97%	Sales Q/Q	-19.02%	Earnings	Oct 31 AMC	Avg Volume	746.04K	Price	7.56
SMA20	0.08%	SMA50	-4.06%	SMA200	-18.67%	Trades		Volume	47,743	Change	-0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
04:05PM	Loading…
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
01:26PM	Loading…
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%
May-21-24 08:17AM	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 (Business Wire) +5.37%
May-13-24 07:21PM	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies (PR Newswire)
May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 09:55AM	Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet (Zacks)
May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Loading…
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)
Nov-30-23 06:10AM	7 Small-Cap Stocks to Buy BEFORE the Year-End Rally (InvestorPlace)
Nov-13-23 08:00AM	Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLDs The Liver Meeting 2023 (Business Wire)
Nov-10-23 08:00AM	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLDs The Liver Meeting 2023 (Business Wire) +7.99%
Nov-08-23 08:05AM	Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (Business Wire)
Nov-04-23 11:42AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:02AM	Q3 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM	Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial Results (GuruFocus.com) +5.13%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-12-23 04:05PM	Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference (GlobeNewswire) -5.98%
Oct-11-23 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Oct-05-23 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-03-23 07:59AM	Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats (GlobeNewswire)
Sep-20-23 08:00AM	Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV (GlobeNewswire)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Sep-08-23 09:34AM	Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls (The Fly)
Aug-29-23 04:30PM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 10:15AM	Is Vir Biotechnology Stock a Buy? (Motley Fool)
Aug-07-23 06:03AM	Analysts Just Made A Major Revision To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Forecasts (Simply Wall St.)
Aug-04-23 01:40PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-21-23 10:11AM	Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues (Zacks) +12.99%
Jul-20-23 04:50PM	Vir's flu-prevention drug fails mid-stage clinical trial, stock dips (American City Business Journals) -44.90%
11:31AM	Why Shares of Vir Biotechnology Are Plunging Thursday (Motley Fool)
08:00AM	Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness (GlobeNewswire)
Jun-29-23 09:00AM	Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer (GlobeNewswire)
Jun-25-23 08:00AM	Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL Congress 2023 (PR Newswire)
Jun-24-23 05:30AM	Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D (GlobeNewswire)
Jun-21-23 08:00PM	VIR: Lowering target price to $26.00 (Argus Research)
Jun-07-23 02:13AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL Congress 2023 (GlobeNewswire)
Jun-05-23 04:05PM	Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-17-23 04:05PM	Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders (GlobeNewswire)
May-16-23 09:25AM	Billionaire Steve Cohen Snaps Up These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks)
May-15-23 08:35AM	Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the company (Simply Wall St.)
08:00AM	Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer (GlobeNewswire)
May-11-23 08:30AM	Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFN and an NRTI (GlobeNewswire)
May-10-23 02:07PM	7 Top-Rated Stocks That Will Boost Your Portfolio in 2023 (InvestorPlace)
May-04-23 07:45PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	The 7 Best Bargain Stocks to Buy for May 2023 (InvestorPlace)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:05PM	Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference (GlobeNewswire)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Napolitano Janet	Director	Sep 09 '24	Sale	7.80	12,190	95,032	11,616	Sep 10 04:28 PM
JANET ANN NAPOLITANO	Director	Sep 09 '24	Proposed Sale	7.76	12,190	94,594		Sep 09 04:29 PM
Ramasastry Saira	Director	Jun 11 '24	Sale	10.95	4,000	43,789	14,619	Jun 12 12:21 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '24	Sale	9.46	72,995	690,365	678,457	Apr 04 04:14 PM
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069	Apr 02 08:58 PM
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492	Mar 28 12:18 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 22 '24	Sale	10.05	12,296	123,521	134,780	Feb 26 07:34 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 22 '24	Sale	10.05	14,568	146,344	250,111	Feb 26 07:31 PM
SCANGOS GEORGE A	Director	Feb 26 '24	Sale	11.65	17,722	206,522	112,989	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 22 '24	Sale	10.05	10,028	100,737	130,711	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 20 '24	Sale	10.22	16,872	172,385	140,739	Feb 20 09:02 PM
SCANGOS GEORGE A	Director	Feb 16 '24	Sale	10.24	10,878	111,386	157,611	Feb 20 09:02 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 16 '24	Sale	10.24	3,321	34,006	264,679	Feb 16 06:56 PM
Pang Phillip	EVP & Chief Medical Officer	Jan 02 '24	Option Exercise	1.38	80,000	110,299	268,000	Jan 03 02:47 PM

RARE

Ultragenyx Pharmaceutical Inc.

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience